Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer
Daniela Weiler1, Joachim Diebold, Klaus Strobel
1*Department of Medical Oncology, Cantonal Hospital, Luzern, Switzerland; †Department of Pathology, Cantonal Hospital, Luzern, Switzerland; and ‡Department of Nuclear Medicine, Cantonal Hospital, Luzern, Switzerland.
Abstract
No abstract available in PubMed .
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11.1K
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
2.9K
Related Concept Videos
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
02:56Treatment Resistent Cancers
1.5K
1.5K